Jerome Waller, MD
Family Medicine · Liberty, SCNPI 1043262868
Payments from drug & device makers
Across 350 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$864
- Novo Nordisk$806
- GSK$682
- AstraZeneca$681
- Boehringer Ingelheim$399
- AbbVie$345
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,456100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 62 | $864 |
| Novo Nordisk | 57 | $806 |
| GSK | 44 | $682 |
| AstraZeneca | 33 | $681 |
| Boehringer Ingelheim | 28 | $399 |
| AbbVie(2 entities) | 22 | $345 |
| Pfizer | 17 | $235 |
| Sanofi-aventis U.S. LLC | 12 | $193 |
| Amgen | 12 | $185 |
| Exact Sciences | 10 | $152 |
| Abbott | 8 | $145 |
| Novartis | 8 | $124 |
| Johnson & Johnson | 5 | $101 |
| Cranial Technologies, Inc | 4 | $75 |
| Dexcom, Inc. | 4 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Idorsia Pharmaceuticals US Inc | 3 | $46 |
| Eisai Inc. | 2 | $37 |
| Phadia US Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Bayer | 2 | $28 |
| Edwards Lifesciences | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,456 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 115 | $109,322 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 145 | $97,186 |
| TrulicityDulaglutide | 56 | $61,749 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $57,064 |
| OzempicSemaglutide | 41 | $45,766 |
| LinzessLinaclotide | 37 | $31,812 |
| RybelsusSemaglutide | 27 | $28,620 |
| XareltoRivaroxaban | 16 | $27,453 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $24,172 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $23,006 |
| MounjaroTirzepatide | 20 | $19,839 |
| EliquisApixaban | 24 | $14,868 |
| JanuviaSitagliptin Phosphate | 17 | $14,843 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $14,148 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $12,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $399 | $109,322115 claims |
| GSKTrelegy Ellipta | $682 | $97,186145 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $864 | $81,58876 claims |
| Novo NordiskOzempic, Rybelsus | $806 | $74,38768 claims |
| MerckJanuvia, Janumet Xr, Janumet, Belsomra | $14 | $48,60463 claims |
| AbbVieLinzess | $345 | $31,81237 claims |
| Johnson & JohnsonXarelto | $101 | $27,45316 claims |
| AstraZenecaBreztri Aerosphere | $681 | $23,00635 claims |
| PfizerEliquis | $235 | $14,86824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Liberty
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.